Company Overview
Company Type: Public Company
Company Status: Operating Subsidiary
Website: ovationscience.com
Number of Employees: -
Ticker: OVAT (CNSX)
Year Founded: 2017


Business Description
Ovation Science Inc. engages in the production, sub-licensing and sales of cannabis or hemp products in Canada, the United States, and Mexico. The company’s Invisicare is a patented drug delivery technology for use in topical and transdermal cannabis products under the Ovation. It offers recreation transdermal cream under the BASKiN names; cannabidiol health and wellness solutions under the Invibe MD name; skincare solutions under the ARLO CBD name; and hand sanitizers under the DermSafe name. Ovation Science Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.1
Market Capitalization
1.3
TEV/Total Revenue
12.8x
EBITDA
(0.8)
Total Enterprise Value
1.4
TEV/EBITDA
NM
EBIT
(0.8)
Cash & ST Invst.
0.0
P/Diluted EPS Before Extra
NM
Net Income
(0.8)
Total Debt
0.1
Price/Tang BV
NM
Total Assets
0.1
Total Debt/EBITDA
NM


Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Howlett, Terry H.
President, CEO & Director
Anderson, Logan B.
CFO, Secretary & Director
McMorran, Doreen 
VP, COO & Independent Director
Ryan, David K.
Head of Investor Relations & Independent Director

Key Board Members
Name
Title
Howlett, Terry H.
President, CEO & Director
Anderson, Logan B.
CFO, Secretary & Director
McMorran, Doreen 
VP, COO & Independent Director
Ryan, David K.
Head of Investor Relations & Independent Director
Chypyha, Joan 
Independent Director
Howard, Ian 
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
625 Howe street Suite 1140 | Vancouver, BC | V6C 2T6 | Canada
Phone: 604-283-0903   

Parent Company
Skinvisible Pharmaceuticals Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.05
Market Cap (mm)
1.3
Open
 0.05
Shares Out. (mm)
29.4
Previous Close
 0.05
Float %
71.2%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.05/ 0.05
Diluted EPS Excl. Extra Items
(0.03)
52 wk High/Low
 0.05/ 0.01
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0010
Avg 3M Dly Vlm (mm)
0.04
Beta 5Y
(0.22)


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
CNSX:OVAT - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
World Rights to DermSafe® Hand Sanitizer
As of February 3, 2020, World Rights to DermSafe® Hand Sanitizer was acquired by Ovation Science Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Oct-03-2023
-
Private Placement
Target
Ovation Science Inc. (CNSX:OVAT)


0.15
May-01-2020
May-27-2020
Private Placement
Target
Ovation Science Inc. (CNSX:OVAT)


1.53
Feb-13-2020
Feb-03-2020
Merger/Acquisition
Buyer
World Rights to DermSafe® Hand Sanitizer
Ovation Science Inc. (CNSX:OVAT)
Skinvisible, Inc. (OTCPK:SKVI)
-
Jun-28-2018
Nov-15-2018
Public Offering
Target
Ovation Science Inc. (CNSX:OVAT)


1.59
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-03-2023
Private Placements
Ovation Science Inc. announced that it expects to receive CAD 0.2 million in funding
Aug-22-2023
Annual General Meeting
Ovation Science Inc., Annual General Meeting, Aug 22, 2023
May-24-2023
Client Announcements
Ovation Science Inc. Signs Exclusive License Agreement for Its Topical Transdermal Cannabis Products for Pennsylvania
Mar-28-2023
Client Announcements
Ovation Science Announces International Supply and Distribution Agreement
Oct-27-2022
Shareholder/Analyst Calls
Ovation Science Inc. - Shareholder/Analyst Call

Competitors
Alternate Health Corp. (OTCPK:AHGI.F), Charlotte's Web Holdings, Inc. (TSX:CWEB), Cresco Labs Inc. (CNSX:CL), Curaleaf Holdings, Inc. (CNSX:CURA), CV Sciences, Inc. (OTCPK:CVSI), Elixinol Wellness Limited (ASX:EXL), Endexx Corporation (OTCPK:EDXC), Eviana Health Corporation, Neuropathix, Inc. (OTCPK:NPTX), Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE)


Advisors
Most Recent Auditor
Dale Matheson Carr-Hilton LaBonte LLP
Public Offering Advisors
Dale Matheson Carr-Hilton LaBonte LLP, Northwest Law Group


Most Recent Auditor
Dale Matheson Carr-Hilton


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Wright Investors' Service Inc.

May 24, 2023 01:46 AM
OVAT
Flow of Funds Report for Ovation Science Inc - prepared by Wright Investors Service
Notes
66


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


McMorran, Doreen 

3,862,250

13.15

0.2

Jul-19-2023


Howlett, Terry H.

3,818,750

13.00

0.2

Jul-19-2023


Chypyha, Joan 

300,000

1.02

0.0

Jul-19-2023


Anderson A.C.A., B.Com., Logan B.

250,001

0.85

0.0

Jul-19-2023


Howard, Ian 

150,000

0.51

0.0

Jul-19-2023


Ryan, David K.

78,000

0.27

0.0

Jul-19-2023


Canaccord Genuity Corp, Asset Management Arm

0

0.00

0.0

Jul-19-2023



 



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Canaccord Genuity Corp, Asset Management Arm
0
(4,000,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-12
Ovation Science Signs License Agreement with Planet 13 for Its Topical, Transdermal Cannabis Products for Nevada
ENP Newswire
Sep-11
PLTH Ovation Science signs licensing deal with Planet 13
Canada StockWatch
Sep-11
Ovation Science Signs License Agreement with Planet 13 for Its Topical / Transdermal Cannabis Products for Nevada
PR Newswire
Sep-11
Ovation Science Signs License Agreement with Planet 13 for Its Topical / Transdermal Cannabis Products for Nevada
Canada Newswire


Company Coverage
This company is not on any Coverage List.

Products
ARLO CBD Beauty (Future), BASKiN, DermSafe Hand Sanitizer, Invibe MD, Licensing of Invisicare


Upcoming Events
Date/Time
Type
Nov-28-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-03-2023
-
Ovation Science Inc. (CNSX:OVAT)
SEDAR
News Releases
121 KB
Aug-29-2023
Jun-30-2023
Ovation Science Inc. (CNSX:OVAT)
SEDAR
Interim Financial Statements
424 KB
Jul-25-2023
-
Ovation Science Inc. (CNSX:OVAT)
SEDAR
Management Proxy Materials
330 KB
Jul-25-2023
-
Ovation Science Inc. (CNSX:OVAT)
SEDAR
Management Proxy Materials
46 KB
Jul-25-2023
-
Ovation Science Inc. (CNSX:OVAT)
SEDAR
Management Proxy Materials
112 KB
Jun-20-2023
-
Ovation Science Inc. (CNSX:OVAT)
SEDAR
Notice of the Meeting and Record Date
178 KB
May-30-2023
Mar-31-2023
Ovation Science Inc. (CNSX:OVAT)
SEDAR
Interim Financial Statements
405 KB
May-24-2023
-
Ovation Science Inc. (CNSX:OVAT)
SEDAR
News Releases
54 KB
May-01-2023
Dec-31-2022
Ovation Science Inc. (CNSX:OVAT)
SEDAR
Annual Financial Statements
74 KB
May-01-2023
Dec-31-2022
Ovation Science Inc. (CNSX:OVAT)
SEDAR
Annual Financial Statements
555 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
McMorran, Doreen  (VP, COO & Independent Director)
Jun-30-2022
Common Shares
13,000
485
Open Market Acquisition
0.34
Multiple
McMorran, Doreen  (VP, COO & Independent Director)
Aug-27-2021
Common Shares
30,500
4,477
Open Market Acquisition
0.80
Multiple
Howard, Ian  (Independent Director)
Jul-10-2020
Common Shares
(50,000)
(26,774)
Open Market Disposition
(25.00)
Exchange Announcement
Howard, Ian  (Independent Director)
Jun-22-2020
Common Shares
(10,000)
(5,339)
Open Market Disposition
(4.76)
Exchange Announcement
Howard, Ian  (Independent Director)
May-27-2020
Common Shares
(20,000)
(8,964)
Open Market Disposition
(8.70)
Exchange Announcement
-
May-27-2020
Common Shares
(15,000)
(6,723)
Open Market Disposition
-
Exchange Announcement
-
May-27-2020
Common Shares
(5,000)
(2,241)
Open Market Disposition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Howlett, Terry H.
President, CEO & Director
604-283-0903
-
terry@skinvisible.com
Anderson, Logan B.
CFO, Secretary & Director
(778) 939-4228
-

McMorran, Doreen 
VP, COO & Independent Director
604-283-0903
-

Ryan, David K.
Head of Investor Relations & Independent Director
(604) 622-1186
604-685-9182
dave@bioharvest.com
Chypyha, Joan 
Independent Director
604-283-0903
-

Howard, Ian 
Independent Director
604-283-0903
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Howlett, Terry H.
President, CEO & Director
604-283-0903
-
terry@skinvisible.com
Anderson, Logan B.
CFO, Secretary & Director
(778) 939-4228
-

McMorran, Doreen 
VP, COO & Independent Director
604-283-0903
-

Ryan, David K.
Head of Investor Relations & Independent Director
(604) 622-1186
604-685-9182
dave@bioharvest.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
